Pfizer Inc. and Merck KGAAreported a Phase III failure for their PD-L1 inhibitor Bavencio (avelumab) in second-line non-small cell lung cancer on Feb. 15, which at least one analyst sees as portending a poor outcome for an ongoing Phase III study in the first-line setting for this tumor type.
The checkpoint inhibitor failed, in the 792-patient JAVELIN Lung 200 study, to meet its primary endpoint of improving overall survival (OS) compared to a control arm of docetaxel chemotherapy in patients with PD-L1-positive tumors whose disease progressed after treatment with platinum-containing doublet therapy
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?